<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01960504</url>
  </required_header>
  <id_info>
    <org_study_id>C1209</org_study_id>
    <nct_id>NCT01960504</nct_id>
  </id_info>
  <brief_title>First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)</brief_title>
  <acronym>BIOSOLVE-II</acronym>
  <official_title>BIOTRONIK - Safety and Clinical PerFormance of the Drug Eluting Absorbable Metal Scaffold (DREAMS 2nd Generation) in the Treatment of Subjects With de NOvo Lesions in NatiVE Coronary Arteries: BIOSOLVE-II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BIOSOLVE-II is a prospective, international, multicenter, First in Man study. The purpose of
      this study is to assess the safety and clinical performance of the drug eluting absorbable
      metal scaffold (DREAMS 2nd Generation).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In segment Late Lumen Loss</measure>
    <time_frame>6 months post index procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure (TLF), defined as composite of cardiac death, target vessel Q-wave or non-Q-wave Myocardial Infarction (MI), Coronary Artery Bypass Graft (CABG), clinically driven Target Lesion Revascularisation (TLR)</measure>
    <time_frame>1, 6, 12, 24 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scaffold thrombosis rate</measure>
    <time_frame>1, 6, 12, 24 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-scaffold and in-segment Binary Restenosis Rate</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-scaffold and in-segment Percent Diameter Stenosis</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Lumen Loss in segment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Lumen Loss in scaffold</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success</measure>
    <time_frame>During the hospital stay to a maximum of the first seven days post index procedure</time_frame>
    <description>Procedure Success defined as achievement of a final diameter stenosis of &lt;30% by QCA, using any percutaneous method, without the occurrence of death, Q-wave or WHO defined non-Q-wave, or repeat revascularization of the target lesion during the hospital stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>Day 0</time_frame>
    <description>Device Success is defined as a final residual diameter stenosis of &lt;30% by QCA, using the assigned device only
successful delivery of the scaffold to the target lesion site in the coronary artery
appropriate scaffold deployment
successful removal of the device
safe removal of the device in case of deployment failure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">121</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>Drug Eluting Absorbable Metal Scaffold</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous Coronary Intervention (DREAMS) stenting</intervention_name>
    <arm_group_label>Drug Eluting Absorbable Metal Scaffold</arm_group_label>
    <other_name>DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is &gt; 18 years and &lt; 80 years of age

          -  Written subject informed consent available prior to PCI

          -  Subjects with stable or unstable angina pectoris or documented silent ischemia

          -  Subject eligible for PCI

          -  Subject acceptable candidate for coronary artery bypass surgery

          -  Subjects with a maximum of two single lesions in two separate coronary arteries which
             have to be de novo lesions.

          -  Reference vessel diameter between 2.2-3.8 mm by visual estimation

          -  Target lesion length ≤ 21 mm by visual estimation

          -  Target lesion stenosis by visual estimation, assisted by QCA / IVUS: &gt; 50% - &lt; 100%

          -  Eligible for Dual Anti Platelet Therapy (DAPT)

        Exclusion Criteria:

          -  Pregnant or breast-feeding females or females who intend to become pregnant during the
             time of the study

          -  Evidence of myocardial infarction within 72 hours prior to index procedure

          -  Subjects with a ≥2 fold CK level or in absence of CK a ≥3 fold CKMB level above the
             upper range limit within 24 hours prior to the procedure

          -  Unprotected left main coronary artery disease

          -  Three-vessel coronary artery disease at time of procedure

          -  Thrombus in target vessel

          -  Subject is currently participating in another study with an investigational device or
             an investigational drug and has not reached the primary endpoint yet

          -  Planned interventional treatment of any non-target vessel within 30 days
             post-procedure

          -  Subjects on dialysis

          -  Planned intervention of the target vessel within 6-month after the index procedure

          -  Ostial target lesion (within 5.0 mm of vessel origin)

          -  Target lesion involves a side branch &gt;2.0 mm in diameter

          -  Documented left ventricular ejection fraction (LVEF) ≤ 30%

          -  Heavily calcified lesion

          -  Target lesion is located in or supplied by an arterial or venous bypass graft

          -  The target lesion requires treatment with a device other than the pre-dilatation
             balloon prior to scaffold placement (including but not limited to, rotational
             atherectomy, cutting balloon etc.)

          -  Known allergies to: Acetylsalicylic Acid (ASA), Heparin, Contrast medium, Sirolimus,
             or similar drugs; or the scaffold material

          -  Impaired renal function (serum creatinine &gt; 2.5 mg/dl or 221 mmol/l, determined within
             72 hours prior to intervention)

          -  Subject is receiving oral or intravenous immuno-suppressive therapy (e.g., inhaled
             steroids are not excluded) or has known life-limiting immunosuppressive or autoimmune
             disease (e.g., human immunodeficiency virus, systemic lupus erythematosus, but not
             including diabetes mellitus)

          -  Proximal or distal to the target lesion located stenosis that might require future
             revascularization or impede run off detected during diagnostic angiography

          -  Life expectancy less than 1 year

          -  Planned surgery or dental surgical procedure within 6 months after index procedure

          -  In the investigators opinion subjects will not be able to comply with the follow-up
             requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Haude, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Städtische Kliniken Neuss</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OLV-Ziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese de Cardiologia</name>
      <address>
        <city>São Paulo</city>
        <zip>04012-909</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto do Coração - HCFMUSP</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segeberg Kliniken GmbH, Herzzentrum</name>
      <address>
        <city>Bad Segeberg</city>
        <zip>D-23795</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtische Kliniken Neuss - Lukaskrankenhaus</name>
      <address>
        <city>Neuss</city>
        <zip>41464</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxcentrum Twente</name>
      <address>
        <city>Enschede</city>
        <zip>7513ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart Centre Singapore</name>
      <address>
        <city>Mistri Wing</city>
        <zip>168752</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUV - Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2013</study_first_submitted>
  <study_first_submitted_qc>October 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2013</study_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DREAMS</keyword>
  <keyword>Drug Eluting Absorbable Metal Scaffold</keyword>
  <keyword>Scaffold</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Myocardial Ischemia</keyword>
  <keyword>Atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

